STAR: A Phase 2, Two-Stage, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns with Moderate or Severe Hypoxic-Ischemic Encep

Grants and Contracts Details

StatusActive
Effective start/end date7/25/237/25/25

Funding

  • ReAlta Life Sciences Incorporated: $11,095.00